Notably, miR-608 targets several inflammation-related transcripts as well as the histocompatibility antigen HLA-DRA (Barbash et al., 2017), which is a biomarker for immunosuppression in sepsis, predictive of survival, and a surrogate marker for GM-CSF experimental therapy of sepsis (Lekkou et al., 2004; Meisel et al., 2009; Cajander et al., 2013). The gene discussed is CSF2; the disease is Sepsis.